Author:
Rossi Raffaella,Granoff Dan M.,Beernink Peter T.
Funder
National Institute of Allergy and Infectious Diseases, NIH
National Center for Research Resources, NIH
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference32 articles.
1. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease;Granoff;Pediatr Infect Dis J,2013
2. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18–36 months: a phase 1 randomized-controlled clinical trial;Marshall;Pediatr Infect Dis J,2012
3. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial;Richmond;The Lancet Infectious Diseases,2012
4. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870;Masignani;J Exp Med,2003
5. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein;Fletcher;Infect Immun,2004
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献